NCT00335894CompletedPhase 3
A Prospective, Randomized, Investigator-blind, Controlled, Clinical Study of Phase III on the Efficacy and Tolerability of hMG-IBSA (IBSA) vs Menopur (Ferring) Administered s.c. in Women Undergoing COH in an ART Programme (IVF)
IBSA Institut Biochimique SA4 sites in 1 country144 target enrollmentStarted: May 1, 2005Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- IBSA Institut Biochimique SA
- Enrollment
- 144
- Locations
- 4
- Primary Endpoint
- total number of oocytes retrieved 34 - 36 hours after hCG administration.
Study Overview
Brief Summary
Multicenter, prospective, randomized, investigator blind, controlled clinical trial. Two parallel groups, one receiving the test drug hMG (hMG-IBSA, IBSA Institut Biochimique sa) and the other the reference drug hMG (Menopur, Ferring Pharmaceuticals, Inc.).
Detailed Description
The purpose of the study is to evaluate the clinical efficacy and general tolerability of two different subcutaneous hMG preparations (hMG-IBSA, IBSA vs Menopur, Ferring Pharmaceuticals, Inc.) when administered to patients undergoing controlled ovarian stimulation for IVF.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Single
Eligibility Criteria
- Ages
- 18 Years to 36 Years (Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Women undergoing ovarian stimulation for IVF with or without ICSI (intracytoplasmic sperm injection) and with the following characteristics:
- •Voluntary given informed consent to study participation in writing encompassing consent to data recording and verification procedures;
- •> 18/= and < 37 years old;
- •BMI between 18 and 28 kg/m2;
- •Less than 3 previous completed IVF cycles;
- •Basal FSH level less than 10 IU/L once within 6 months prior to the study;
- •Within 12 month of the beginning of the study, uterine cavity consistent with expected normal function as assessed through a hysterosalpingogram, or sonohysterogram, or hysteroscopic examination or TVUS;
- •Normal or clinically insignificant haematology and blood chemistry values.
Exclusion Criteria
- •Primary ovarian failure or women known as poor responders;
- •Signs of PCO, according to the Rotterdam Criteria;
- •At least one ovary inaccessible for oocyte retrieval;
- •One or more ovarian cysts > 10 mm;
- •Hydrosalpinx that have not been surgically removed or ligated;
- •Stage III or IV endometriosis;
- •Patients affected by pathologies associated with any contraindication of being pregnant;
- •Hypersensitivity to the study medication;
- •Abnormal bleeding of undetermined origin;
- •Uncontrolled thyroid or adrenal dysfunction;
- •Neoplasias;
- •PAP smear III within the last 2 years;
- •Severe impairment of the renal and/or hepatic functions;
- •Lactation;
- •Hyperprolactinaemia;
- •Participation in a concurrent clinical trial or in another trial within the past four weeks;
- •Use of concomitant medication that might interfere with study evaluations.
Outcomes
Primary Outcomes
total number of oocytes retrieved 34 - 36 hours after hCG administration.
Secondary Outcomes
- Total dose of hMG (IU); number of days of hMG stimulation and stimulation duration; cancellation rate with reasons; 17β-estradiol (E2) serum concentration; number of follicles >16 mm.
- number of mature oocytes and inseminated oocytes; fertilization rate.
- embryo score; number of transferred embryos; implantation rate, number of transferred embryos; clinical pregnancy rate
- Tolerability evaluation
Investigators
Study Sites (4)
Loading locations...
Similar Trials
Completed
Not Applicable
Clinical Study Evaluating Effects of Pharmacogenetic-guided vs Standard-of-Care Treatment on Depression and/or AnxietyDepressionAnxietyNCT02878928AltheaDx579
Completed
Phase 3
Efficiency Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With RisperidoneSchizophreniaNCT01516424Sumitomo Pharma (Suzhou) Co., Ltd.267
Completed
Phase 3
Fixed-dose Combination of Oxycodone [OXIcodona] + IbuproFEN in Pain Relief After Third Molar ExtractionPainNCT05081102Eurofarma Laboratorios S.A.288
Completed
Phase 3
Fixed Dose Combination of COdeine + DIpyrone to Mitigate Moderate to Intense Pain Post-impacted Third Lower Molar ExtractionPainNCT04972292Eurofarma Laboratorios S.A.288
Completed
Not Applicable
Efficacy and Safety of the DTS-G2 System in Patients With Axillary HyperhidrosisPrimary Focal Hyperhidrosis, AxillaNCT00931359Miramar Labs120